Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: Seeking Alpha
R. Townsend - CEO & Director Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division Presentation Debjit Chattopadhyay Guggenheim Securities, LLC, Research Division Good afternoon, and thank you for joining Guggenheim's 2026 Emerging Outlook Biotech Summit. I'm Debjit, one of the therapeutic analysts and my privilege to welcome my next presenting company, Lexeo Therapeutics. And from Lexeo, I have Nolan Townsend, the CEO; and Louis Tamayo, the CFO. Thank you, gentlemen. R. Townsend CEO & Director Thank you. It's great to be here. Thanks for having us at the conference. Debjit Chattopadhyay Guggenheim Securities, LLC, Research Division If I could ask you just do a quick intro before we get into the Q&A. R. Townsend CEO & Director Yes, sure. So Lexeo is a cardiac genetic medicines company. Our most advanced programs, utilizing AAV gene therapy to correct genetic cardiovascular diseases of high unmet need. Our most
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics to Participate in Upcoming Investor Conferences in FebruaryGlobeNewswire
- H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA TherapeuticsGlobeNewswire
- Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
LXEO
Earnings
- 8/14/25 - Beat
LXEO
Sec Filings
- 2/13/26 - Form SCHEDULE
- 2/6/26 - Form 4
- 2/6/26 - Form 4
- LXEO's page on the SEC website